Search
moon
sun

T227. Hyperosmolar hyperglycemic state (HHS)

A. Introduction and epidemiology

1.
Hyperosmolar hyperglycemic state (HHS) : Hyperlycemia & Hyperosmolarity (1) ํ˜ˆ๋‹น ์กฐ์ ˆ์ด ๋˜์ง€ ์•Š๋Š” ํ˜น์€ ์ง„๋‹จ๋˜์ง€ ์•Š์€ type 2 DM, ์ˆ˜๋ถ„ ์ œํ•œ, ์ด‰๋ฐœ์‹œํ‚ค๋Š” ๋ณ‘์ด ์žˆ๊ณ  ์‡ ์•ฝํ•œ ํ™˜์ž์—์„œ ์ฃผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. (2) ๋Œ€๋ถ€๋ถ„์€ ์žˆ๋Š” ๊ณ ๋ น์˜ ํ™˜์ž์ด๋‚˜ ์†Œ์•„์˜ ๋ฐœ๋ณ‘๋ฅ  ์ƒ์Šน ์ค‘ (3) Common risk factor : Obesity, African American

B. Pathophysiology

1.
HHS์˜ ๋ฐœ๋ณ‘์— ๊ด€์—ฌํ•˜๋Š” 3๊ฐ€์ง€ ์ฃผ์š” ์ธ์ž๋Š” (1) Insulin resistance and/or deficiency (2) Inflammatory state : Proinflammatory cytokines๊ณผ counterregulatory hormones์˜ ์ฆ๊ฐ€๋กœ ์ธํ•ด gluconeogenesis ๋ฐ glycogenolysis์˜ ์ฆ๊ฐ€ (3) Osmotic diuresis (glucose์˜ renal excretion ๊ฐ์†Œ)
2.
T2DM ํ™˜์ž์—์„œ๋Š” physiologic stresses์™€ inadequate water intake๋กœ ๋ฐœ์ƒ๋œ๋‹ค.

C. Clinical features

C1. History and Comorbidities

โ€ข
์ „ํ˜•์ ์ธ HHS ํ™˜์ž๋Š” ๋Œ€๊ฐœ๋Š” ๊ณ ๋ น์— ์ž…์› ์ค‘์ธ ํ™˜์ž์ด๋ฉฐ ๊ธฐ์ € ์ธ์ง€ ์žฅ์• ๊ฐ€ ์žˆ์œผ๋ฉฐ ๋™๋ฐ˜ ์งˆํ™˜์„ ๊ฐ€์ง„ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์œผ๋ฉฐ ์ด๋Ÿฐ ํ™˜์ž์—์„œ v/s, lab, m/s๊ฐ€ ๋ฉฐ์น ์—์„œ ๋ช‡ ์ฃผ์— ๊ฑธ์ณ ์•…ํ™”๋˜์–ด ์˜๋ขฐ๋˜๊ฒŒ ๋œ๋‹ค.
โ€ข
์•ฝ 15%๊นŒ์ง€ ๊ฒฝ๋ จ์„ ๋ณด์ด๊ธฐ๋„ ํ•˜๋ฉฐ ์ฃผ๋กœ ๋ถ€๋ถ„ ๋ฐœ์ž‘์ด๋‚˜ ์ „์‹ ๋ฐœ์ž‘์„ ํ•˜๊ธฐ๋„ ํ•œ๋‹ค.
โ€ข
์ฃผ์š” ์ฆ์ƒ์€ nonspecificํ•˜๋ฉฐ malaise, weakness, anorexia, fatigue, vomiting, cognitive impairment๊ฐ€ ํฌํ•จ๋œ๋‹ค.
โ€ข
์–ด๋А ๊ฒฝ์šฐ๋Š” DM hx๊ฐ€ ์—†๋Š” ํ™˜์ž์—๊ฒŒ์„œ stroke, MI, pneumonia, abdominal emergencies, sepsis์‹œ ๋‚˜ํƒ€๋‚˜๊ธฐ๋„ ํ•œ๋‹ค.
โ€ข
Antipsychotics๋‚˜ antidepressants๋ฅผ ๋ณต์šฉํ•˜๋Š” ํ™˜์ž๋„ risk.
โ€ข
HHS๋Š” ํ™˜์ž์˜ condition์ด๋‚˜ ์•ฝ๋ฌผ์— ์˜ํ•ด ๋” ํ˜ธ๋ฐœ ๊ฐ€๋Šฅํ•˜๋‹ค.

C2. Physical examination

โ€ข
HHS์—์„œ ๋ณด์ด๋Š” physical ์–‘์ƒ์€ nonspecific, ์ผ๋ฐ˜์ ์œผ๋กœ volume depletion ์ƒํƒœ์—์„œ ๊ด€์ฐฐ๋˜๋Š” ์–‘์ƒ๊ณผ ๋น„์Šทํ•œ ์–‘์ƒ์„ ๋ณด์ธ๋‹ค.
โ€ข
Lethargy์˜ ์ •๋„ ๋ฐ ํ˜ผ์ˆ˜ ์—ฌ๋ถ€๋Š” serum osmolality์™€ ๋น„๋ก€ํ•œ๋‹ค.
โ€ข
ํ˜ผ์ˆ˜๊ฐ€ ์žˆ๋Š” ํ™˜์ž๋Š” ์ฃผ๋กœ ๋‚˜์ด๊ฐ€ ๋” ๋งŽ๊ณ . osmol๋„ ๋” ๋†’๊ณ . ํ˜ˆ๋‹น๋„ ๋” ๋†’๊ณ , acidosis๋„ ์‹ฌํ•˜๊ณ . ์ˆ˜๋ถ„๋„ ๋” ๊ณ ๊ฐˆ๋œ ์ƒํƒœ์ด๋‹ค.

D. Diagnosis and differential diagnosis

D1. HHS

(1) Severe hyperglycemia (serum glucose >600 mg/dL) (2) Calculated plasma osmolality >315 mOsm/kg (3) Serum bicarbonate >15 mEq/L (4) arterial pH >7.3 (5) Serum ketone negative to mildly positive
โ€ข
HHS์—์„œ ์—ฌ๋Ÿฌ ํ˜•ํƒœ์˜ mixed acid-base pattern์ด ๋ณด์ผ ์ˆ˜ ์žˆ์Œ์„ ์•Œ๊ณ  ์žˆ์–ด์•ผ ํ•œ๋‹ค.

D2. Laboratory testing and imaging

(1) Sodium

โ€ข
Hyperglycemia์—์„œ serum sodium์„ ์ธก์ •ํ•  ๋•Œ dilutional effect๋ฅผ ๊ฐ–๋Š”๋‹ค.
โ€ข
Serum glucose 100~400mg/dL์ธ ๊ฒฝ์šฐ์—์„œ serum glucose๊ฐ€ ๋งค 100mg/dL์˜ ์ฆ๊ฐ€๋งˆ๋‹ค Serum Na+๋Š” 1.6 mEq/L๊ฐ€ ๊ฐ์†Œํ•œ๋‹ค. glucose > 400์ธ ๊ฒฝ์šฐ 2.4mEq/L

(2) Osmolality

โ€ข
Serum osmolality ๋Š” ์งˆ๋ณ‘์˜ severity ๋ฐ mental status change์—์„œ positive correlation๋œ๋‹ค.
โ€ข
๋ฏธ๊ตญ์—์„œ๋Š” urea๋ฅผ ์ œ์™ธํ•œ calculated effective serum osmolality๋ฅผ ๊ถŒ๊ณ ํ•˜๋‚˜ ์˜๊ตญ์—์„œ๋Š” urea๊ฐ€ ํฌํ•จ๋œ ๊ณ„์‚ฐ์‹์ด ํƒˆ์ˆ˜์˜ ์ •๋„๋ฅผ ๋” ์ •ํ™•ํžˆ ๋ฐ˜์˜ํ•œ๋‹ค๊ณ  ๋ณด๊ณ  ์žˆ๋‹ค.
โ€ข
์ •์ƒ์น˜ 275~295 mOsm/kg, >300์ด๋ฉด significant hyperosmolality๊ฐ€ ์žˆ๋‹ค๊ณ  ๋ณด๋ฉฐ >320์ด๋ฉด cognitive function์— ์˜ํ–ฅ์„ ์ค€๋‹ค. ๊ต์ •์€ 3.0 Osm/kg/h๋ฅผ ๋„˜์ง€ ์•Š๋Š”๋‹ค.

(3) Potassium

โ€ข
ํ‰๊ท ์ ์œผ๋กœ potassium loss๋Š” 4~6mEq/kg
โ€ข
์ด๋ ‡๊ฒŒ deficit์ด ์žˆ์Œ์—๋„, acidemia ์ƒํƒœ์—์„œ๋Š” ์ดˆ๊ธฐ lab์—์„œ ์ •์ƒ ํ˜น์€ ๋†’๊ฒŒ ์ธก์ •๋  ์ˆ˜ ์žˆ๋‹ค.
โ€ข
Fluid ๋ณด์ถฉ์ด ๋˜๊ณ  acidemia๊ฐ€ ๊ต์ •๋˜๋ฉฐ K+ deficiency๊ฐ€ ๋” ๋ช…๋ฐฑํ•ด์ง„๋‹ค.

E. Treatment

โ€ข
Tissue perfusion์„ ํ–ฅ์ƒ์‹œํ‚ค๋Š” ๊ฒƒ์ด ์ค‘์š”.
โ€ข
Hypovolemia๋ฅผ ์น˜๋ฃŒํ•˜๋Š” ๋™์‹œ์— precipitating cause์™€ ์ „ํ•ด์งˆ ๋ถˆ๊ท ํ˜•์„ ๊ต์ •ํ•˜๊ณ  ์„œ์„œํžˆhyperglycemia์™€ hyperosmolarity๋ฅผ ๊ต์ •ํ•œ๋‹ค.
โ€ข
๊ณผ๋„ํ•œ resuscitation์€ ์˜คํžˆ๋ ค ํ•ด๋ฅผ ๋ผ์น  ์ˆ˜ ์žˆ์–ด ์กฐ์‹ฌํ•ด์•ผ ํ•œ๋‹ค.

E1. Fluid resuscitation

โ€ข
Fluid resuscitation์œผ๋กœ volume์„ ๋ณด์ถฉํ•ด์ฃผ๊ณ  tissue perfusion์„ ํ–ฅ์ƒ์‹œํ‚ค๋ฉฐ serum glucose๋ฅผ 35~70mg/dL/hr ๊ฐ€๋Ÿ‰ ๊ฐ์†Œ์‹œํ‚จ๋‹ค.
โ€ข
Insulin therapy๋ฅผ ์‹œ์ž‘ํ•˜๊ธฐ ์ „์— N/S infusion ํ•œ๋‹ค.
โ€ข
ํ‰๊ท ์ ์ธ fluid deficit์€ total body water์˜ 20~25%๊ฐ€๋Ÿ‰, 8~12L ์ •๋„์ด๋‹ค.
โ€ข
์ฒ˜์Œ 12์‹œ๊ฐ„์˜ ์น˜๋ฃŒ์—์„œ fluid deficit์˜ 1/2๋ฅผ ์ฃผ๊ณ  ๋‚˜๋จธ์ง€๋ฅผ ๋‹ค์Œ 24์‹œ๊ฐ„ ๋™์•ˆ์— ์ค€๋‹ค.
โ€ข
๊ฐ ํ™˜์ž์˜ ์‹ฌ๊ธฐ๋Šฅ, ์‹ ๊ธฐ๋Šฅ์— ๋”ฐ๋ผ ์ฐจ๋ณ„ํ™”๋œ ์น˜๋ฃŒ๊ฐ€ ํ•„์š”ํ•˜๋‹ค.
โ€ข
0.9% N/S๋ฅผ ์ฒซ 1์‹œ๊ฐ„ ๋™์•ˆ์—๋Š” 15~20mL/kg/hr ๋กœ ์ฃผ๊ณ , ๋‹ค์Œ์€ 4~14mL/kg/h๋กœ ์ค€๋‹ค.
โ€ข
์ฒ˜์Œ 4์‹œ๊ฐ„์—์„œ๋Š” <50 mL/kg ์ดํ•˜๋กœ N/S ํˆฌ์—ฌ๋ฅผ ์ œํ•œํ•œ๋‹ค. ์ดํ›„ ์ €ํ˜ˆ์••, ๋นˆ๋งฅ, ์ €๋‚˜ํŠธ๋ฅจ, urine output ํ˜ธ์ „ ์‹œ 0.45% N/S๋ฅผ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค.

E2. Electrolytes

(1) K

โ€ข
Hypokalemia๊ฐ€ dysrhythmia์˜ ์œ„ํ—˜์š”์†Œ๊ฐ€ ๋จ์œผ๋กœ volume repletion ๋ฐ insulin ์‚ฌ์šฉ ์‹œ์—๋Š” ๋ฐ˜๋“œ์‹œ replace ํ•ด์ฃผ์–ด์•ผ ํ•œ๋‹ค.
โ€ข
์ผ๋ฐ˜์ ์œผ๋กœ 10~20mEq/h๋กœ ํˆฌ์—ฌํ•˜๋ฉฐ, life threateningํ•œ ๊ฒฝ์šฐ infusion rate์„ 40mEq/h๊นŒ์ง€ ๋†’์ผ ์ˆ˜ ์žˆ๋‹ค. ์ด๋Ÿฐ ๊ฒƒ์„ ๊ณ ๋ คํ•˜์—ฌ central catheter ์‚ฝ์ž…์„ ๊ถŒ๊ณ ํ•œ๋‹ค.

(2) Magnesium

โ€ข
deficit์—์„œ๋Š” 1~2g์„ 1์‹œ๊ฐ„ ๋™์•ˆ ํˆฌ์—ฌ.

(4) Phosphate

โ€ข
1.0mg/dL์‹œ์—๋งŒ replaceํ•ด์ค€๋‹ค.

(5) Sodium bicarbonate

โ€ข
pH <7.0์—์„œ ํˆฌ์—ฌ ๊ถŒ๊ณ ๋ฅผ ํ•˜์ง€๋งŒ ๋”์šฑ ์ตœ๊ทผ study์—์„œ๋Š” ์†Œ์•„์—์„œ๋Š” ๋“์€ ์—†๊ณ  ์ž ์žฌ์  ํ•ด๋งŒ ์žˆ๋‹ค๊ณ  ๋ณธ๋‹ค.

E3. Insulin

โ€ข
Insulin์€ ์ดˆ๊ธฐ fluid resuscitation์ด ์™„๋ฃŒ๋œ ํ›„์— ํˆฌ์—ฌํ•œ๋‹ค.
โ€ข
IM ํ˜น์€ SC๋กœ ์ฃผ๋Š” insulin์˜ ํก์ˆ˜๋Š” HHS ํ™˜์ž์— ์žˆ์–ด์„œ๋Š” unreliableํ•˜๊ณ , continuous infusion์ด๊ถŒ์œ ๋œ๋‹ค.
โ€ข
0.1 unit/kg/h๋กœ continuous infusion์œผ๋กœ ์‹œ์ž‘ํ•œ๋‹ค.
โ€ข
ํ˜ˆ๋‹น์€ 50~75mg/dL/h ์†๋„๋กœ ๊ฐ์†Œ๊ฐ€ ์ด์ƒ์ ์ด๊ณ  ๊ฐ๋Ÿ‰ ์†๋„๋ฅผ ์ผ์ •ํ•˜๊ฒŒ ํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”. โ‡’ ๋งค ์‹œ๊ฐ„๋งˆ๋‹ค checkํ•˜์—ฌ infusion rate๋ฅผ ์ ์ ˆํžˆ ์กฐ์ ˆ.
โ€ข
<300mg/dL์ด ๋˜๋ฉด D5 1/2NS๋กœ ๋ฐ”๊พธ๊ณ  insulin์€ 0.02~0.05 unit/kg/h๋กœ ์œ ์ง€ํ•œ๋‹ค. (Target : serum osmolality <315 mOsm/kg, glucose 200~300 mg/dL)

F. Disease complications

โ€ข
Cerebral edema๋Š” ์†Œ์•„ ์‚ฌ๋ง์ž์˜ >50%์—์„œ ๋ณด์ด๋‚˜ ์„ฑ์ธ์—์„œ๋Š” ํ”์น˜ ์•Š์Œ.
โ—ฆ
Osmolality์˜ ๊ธ‰๊ฒฉํ•œ ๋ณ€ํ™”๊ฐ€ osmotic demyelination SD์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค๋Š” ๋ณด๊ณ ๊ฐ€ ์žˆ๋‹ค.
โ—ฆ
ํ˜„์žฌ ๊ถŒ๊ณ ์‚ฌํ•ญ์€ ์ฒซ 4์‹œ๊ฐ„์— <50mL/kg of N/S ๋ณด์ถฉํ•˜๊ณ  ์ž์ฃผ serum osmol checkํ•˜๊ณ  ์น˜๋ฃŒ ์ค‘์ฃผ๊ธฐ์ ์ธ ํ™˜์ž ์˜์‹ ์ƒํƒœ๋ฅผ ๋ชจ๋‹ˆํ„ฐํ•˜๋Š” ๊ฒƒ์ด๋‹ค.
โ—ฆ
์˜์‹์ด ๋” ์ณ์งˆ ์‹œ state head CT ๋˜๋Š” MRI ๋ฐ neuro consult๊ฐ€ ํ•„์š”ํ•˜๋‹ค.
โ€ข
์ •๋งฅ/๋™๋งฅ ํ˜ˆ์ „์€ HHS์˜ ํ”ํ•œ ํ•ฉ๋ณ‘์ฆ์œผ๋กœ ๊ธˆ๊ธฐ๊ฐ€ ์•„๋‹ˆ๋ผ๋ฉด ์น˜๋ฃŒ ๊ณ„ํš์— ์˜ˆ๋ฐฉ์  ํ•ญ์‘๊ณ ์ œ๋ฅผ ํฌํ•จ์‹œํ‚ค๋Š” ๊ฒƒ์ด ์ข‹๋‹ค.

G. Disposition and Follow-up

โ€ข
์ฒซ 24์‹œ๊ฐ„ ๋™์•ˆ ICU์—์„œ ๋ชจ๋‹ˆํ„ฐ.
โ€ข
์ดˆ๊ธฐ ์น˜๋ฃŒ์— ๋ฐ˜์‘ ์ข‹๊ณ  comorbid condition์ด ์—†๋Š” ๊ฒฝ์šฐ non ICU ์ž…์› ๊ณ ๋ ค